news and updates

12.21.2015

AureoGen closes a licensing agreement with Merck.

read more ...

contact us

AureoGen Biosciences 
4717 Campus Drive Suite 2300 
Kalamazoo, MI 49008 
1.269.353.3805   

funding

AureoGen has to date raised approximately $8.3 million from the following sources: 

$200,000. Start-up funding from the Michigan Economic Development Corporation (MEDC), September 4th 2003.

$1,994,476. A convertible loan from the Michigan Tri-Technology Corridor (MTTC), for development of genetic tools and methodologies for efficient engineering of cyclic peptide producing organisms, June 29th, 2004.

$162,982. Phase I SBIR grant from the National Institutes of Health (NIH), for a project entitled Novel Antifungals by Engineering a NRPS gene, September 17th, 2004.

$1,450,508. Three year grant from the National Institutes of Standards and Technology, Advanced Technology Program (NIST/ATP), for a project entitled “A Genetic Engineering Technology Platform for Production of Novel Cyclic Peptide-Based Drugs, September 28th, 2004.

$225,000. Investment/convertible loan from the Western Michigan University (WMU) Bioscience Research and Commercialization Center (BRCC), April 1, 2005.

$1,978,701. Three year SBIR grant from the National Institutes of Health (NIH), for Phase II of the project Novel Antifungals by Engineering a NRPS gene, May 15th, 2006.

$381,116. SBIR Phase I grant entitled, A Bacitracin derivative for systemic use, awarded June 22, 2007

$600,000. SBIR Phase I ATP grant (two years) entitled, Generation of novel HCV drugs through engineering of the cssA gene, awarded March 27, 2008.

$286,746. SBIR Phase I grant entitled, Generation of novel drugs against drug resistant bacteria through engineering of the empedopeptin biosynthesis gene, awarded June 13, 2008

$244,479. Qualifying Therapeutic Discovery Project award, October 29, 2010

$487,411. Competitive renewal of NIH Phase II SBIR grant for the project Novel Antifungals by Engineering a NRPS gene, Feb 11th, 2011.

$340,000. Investment/convertible loan from the Western Michigan University (WMU) Bioscience Research and Commercialization Center (BRCC), January 31, 2014.

The company is actively pursuing additional funding from both public and private sources.